- 英文名称
- Alisporivir
- 分子式
- C63H113N11O12
- 分子量
- 1216.64
- 中文别名
- (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-25,30-二乙基-33-((1R,2R,E)-1-羟基-2-甲基己-4-烯-1-基)-6,9,18-三异丁基-3,21,24-三异丙基-1,4,7,10,12,15,19,27,28-九甲基-1,4,7,10,13,16,19,22,25,28,31-十一氮杂环三十三碳-2,5,8,11,14,17,20,23,26,29,32-十一酮; 化合物 T14180; ALISPORIVIR游离态; 环[L-丙氨酰-D-丙氨酰-N-甲基-L-亮氨酸-N-甲基-L-亮氨酸-N-甲基-L-缬氨酸-(2S,3R,4R,6E)-3-羟基-4-甲基-2-(甲氨基)-6-辛烯基-(2S)-2-氨基丁酰基-N-甲基-D-丙氨酰-N-乙基-L-缬氨酸-L-缬氨酸-N-甲基-L-亮氨酸]; 化合物 Alisporivir; (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-25,30-Diethyl-33-((1R,2R,E)-1-hydroxy-2-methylhex-4-en-1-yl)-6,9,18-triisobutyl-3,21,24-triisopropyl-1,4,7,10,12,15,19,27,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone; (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-25,30-Diethyl-33-[(1R,2R,4E)-1-hydroxy-2-methyl-4-hexen-1-yl]-6,9,18-triisobutyl-3,21,24-triisopropyl-1,4,7,10,12,15,19,27,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; Debio 025; DEB025; alisporivir; DEB-025; Debio-025; Cyclo[L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-(2S,3R,4R,6E)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl-(2S)-2-aminobutanoyl-N-methyl-D-alanyl-N-ethyl-L-valyl-L-valyl-N-methyl-L-leucyl]
- 用途
- 化学合成；作为亲环蛋白抑制剂，具有高效抗丙型肝炎病毒(HCV)活性；体外可抑制HCV复制，阻止HCV蛋白介导的线粒体膜电位崩溃及线粒体功能障碍，低 micromolar 剂量可阻断SARS-CoV和MERS-CoV复制，与ICN-1229联用可增强抗MERS-CoV活性，预处理可刺激肝癌靶细胞抗原呈递，增强抗原特异性CD8+T细胞活化，诱导多种细胞系表面MHC-I和β-2微球蛋白增加；体内与ICN-1229联用对小鼠SARS-CoV感染无保护作用
